OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)

Juvenile arthritis — is the most common chronic rheumatic disorder among children, which causes rapid development of disability, decrease of the quality of life, social and psychological dysadaptation. In the majority of cases the main pathogenetic treatment is methotrexate, however when there is re...

Full description

Saved in:
Bibliographic Details
Main Authors: G. A. Shebaev, R. M. Shakirova, V. A. Malievskii, R. Z. Akhmetshin
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2013-12-01
Series:Вопросы современной педиатрии
Subjects:
Online Access:https://vsp.spr-journal.ru/jour/article/view/262
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850024301226360832
author G. A. Shebaev
R. M. Shakirova
V. A. Malievskii
R. Z. Akhmetshin
author_facet G. A. Shebaev
R. M. Shakirova
V. A. Malievskii
R. Z. Akhmetshin
author_sort G. A. Shebaev
collection DOAJ
description Juvenile arthritis — is the most common chronic rheumatic disorder among children, which causes rapid development of disability, decrease of the quality of life, social and psychological dysadaptation. In the majority of cases the main pathogenetic treatment is methotrexate, however when there is resistance or intolerability of this drug, therapy with genetically engineered biological agents is indicated. Aim: to develop measures of optimization of medical support for children with juvenile arthritis according to analysis of its medical and social as well as economic consequences at regional level. Patients and methods: the epidemiologic study included screening questionnaires of 43 907 children with subsequent examination of those of them with inflammatory swelling of the joints during 1 year. Formation of regional registry of children with juvenile arthritis has been performed in the Republic of Bashkortostan since 2003, regional component of the federal on-line registry has been functioning since 2011. The prevalence of juvenile arthritis, its social and economic consequences and the «costs of the disease» were established. In total there were registered 474 patients with juvenile arthritis, among them 62 receive treatment with genetically engineered biological agents. Results: an order of providing the children with juvenile arthritis with medical agents is established — in-patient treatment is performed within the framework of specialized (including high-tech) medical care; genetically engineered biological drugs for out-patient therapy are purchased at the expense of republican state resources in the network of the social support of certain population groups («regional benefit»).
format Article
id doaj-art-afe5af30835b4fbba01393e95e7fd4ab
institution DOAJ
issn 1682-5527
1682-5535
language English
publishDate 2013-12-01
publisher "Paediatrician" Publishers LLC
record_format Article
series Вопросы современной педиатрии
spelling doaj-art-afe5af30835b4fbba01393e95e7fd4ab2025-08-20T03:01:08Zeng"Paediatrician" Publishers LLCВопросы современной педиатрии1682-55271682-55352013-12-01126858910.15690/vsp.v12i6.880262OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)G. A. Shebaev0R. M. Shakirova1V. A. Malievskii2R. Z. Akhmetshin3Ministry of Healthcare of the Republic of Bashkortostan, Ufa, Republic of BashkortostanMinistry of Healthcare of the Republic of Bashkortostan, Ufa, Republic of BashkortostanBashkir State Medical University, Ufa, Republic of BashkortostanRepublican Pediatric Clinical Hospital, Ufa, Republic of BashkortostanJuvenile arthritis — is the most common chronic rheumatic disorder among children, which causes rapid development of disability, decrease of the quality of life, social and psychological dysadaptation. In the majority of cases the main pathogenetic treatment is methotrexate, however when there is resistance or intolerability of this drug, therapy with genetically engineered biological agents is indicated. Aim: to develop measures of optimization of medical support for children with juvenile arthritis according to analysis of its medical and social as well as economic consequences at regional level. Patients and methods: the epidemiologic study included screening questionnaires of 43 907 children with subsequent examination of those of them with inflammatory swelling of the joints during 1 year. Formation of regional registry of children with juvenile arthritis has been performed in the Republic of Bashkortostan since 2003, regional component of the federal on-line registry has been functioning since 2011. The prevalence of juvenile arthritis, its social and economic consequences and the «costs of the disease» were established. In total there were registered 474 patients with juvenile arthritis, among them 62 receive treatment with genetically engineered biological agents. Results: an order of providing the children with juvenile arthritis with medical agents is established — in-patient treatment is performed within the framework of specialized (including high-tech) medical care; genetically engineered biological drugs for out-patient therapy are purchased at the expense of republican state resources in the network of the social support of certain population groups («regional benefit»).https://vsp.spr-journal.ru/jour/article/view/262childrenjuvenile arthritisnational registrycosts of treatment
spellingShingle G. A. Shebaev
R. M. Shakirova
V. A. Malievskii
R. Z. Akhmetshin
OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
Вопросы современной педиатрии
children
juvenile arthritis
national registry
costs of treatment
title OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
title_full OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
title_fullStr OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
title_full_unstemmed OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
title_short OPTIMIZATION OF HEALTHCARE FOR CHILDREN WITH RHEUMATIC DISEASES IN EPOCH OF TREATMENT WITH GENETICALLY ENGINEERED BIOLOGICAL AGENTS (BY THE EXAMPLE OF THE REPUBLIC OF BASHKORTOSTAN)
title_sort optimization of healthcare for children with rheumatic diseases in epoch of treatment with genetically engineered biological agents by the example of the republic of bashkortostan
topic children
juvenile arthritis
national registry
costs of treatment
url https://vsp.spr-journal.ru/jour/article/view/262
work_keys_str_mv AT gashebaev optimizationofhealthcareforchildrenwithrheumaticdiseasesinepochoftreatmentwithgeneticallyengineeredbiologicalagentsbytheexampleoftherepublicofbashkortostan
AT rmshakirova optimizationofhealthcareforchildrenwithrheumaticdiseasesinepochoftreatmentwithgeneticallyengineeredbiologicalagentsbytheexampleoftherepublicofbashkortostan
AT vamalievskii optimizationofhealthcareforchildrenwithrheumaticdiseasesinepochoftreatmentwithgeneticallyengineeredbiologicalagentsbytheexampleoftherepublicofbashkortostan
AT rzakhmetshin optimizationofhealthcareforchildrenwithrheumaticdiseasesinepochoftreatmentwithgeneticallyengineeredbiologicalagentsbytheexampleoftherepublicofbashkortostan